Trinity Biotech Plc (TRIB) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Trinity Biotech Plc (TRIB) stock forecast summary
On Oct. 14, 2026, TRIB is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 4009 stocks scored that day.
Its market capitalization is not available, so no size classification is given.
A per-ticker accuracy statistic for TRIB is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +4.5%, buy ≥ +3.4%, sell < +2.1%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, TRIB included.
Follow TRIB freeTRIB price chart and AI forecast
How TRIB ranks among 4009 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trinity Biotech Plc (TRIB) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the In Vitro & In Vivo Diagnostic Substances peers listed below that report each metric.
Financial statement data is not available for this company: its filings are not in a form the pipeline converts, so only market data is shown.
TRIB quarterly financials and insider trading
Trinity Biotech Plc (TRIB) industry peers
Companies classified under the same SEC industry code as Trinity Biotech Plc (In Vitro & In Vivo Diagnostic Substances): 17 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| TRIB Trinity Biotech Plc | ▶ | N/A |
| IDXX Idexx Laboratories Inc /De | ▼ | $40.99B |
| LNTH Lantheus Holdings, Inc. | ▼ | $6.53B |
| NEOG Neogen Corp | ▲ | $2.56B |
| CLDX Celldex Therapeutics, Inc. | ▲ | $2.22B |
| NTLA Intellia Therapeutics, Inc. | ▲ | $1.67B |
| QDEL Quidelortho Corp | ▲ | $967M |
| ACHV Achieve Life Sciences, Inc. | ▲ | $720M |
| TKNO Alpha Teknova, Inc. | ▲ | $441M |
| MYGN Myriad Genetics Inc | ▲ | $390M |
| ICCC Immucell Corp /De/ | ▲ | $98M |
| IMDX Insight Molecular Diagnostics Inc. | ▲ | $98M |
| AWHL Aspira Women's Health Inc. | ▲ | $12M |
| BMRA Biomerica Inc | ▲ | $8M |
| CDIO Cardio Diagnostics Holdings, Inc. | ▲ | $5M |
| VNRX Volitionrx Ltd | ▶ | $3M |
| QCLS Q/C Technologies, Inc. | ▼ | N/A |
Where TRIB sits on the market map
Trinity Biotech Plc (TRIB) stock news
Loading...
Trinity Biotech Plc (TRIB) stock forecast FAQ
What is the Trinity Biotech Plc (TRIB) stock forecast?
On Oct. 14, 2026, TRIB is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 4009 stocks scored that day.
How accurate are Trinity Biotech Plc stock predictions?
A per-ticker accuracy statistic for TRIB is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Trinity Biotech Plc forecasts updated?
Trinity Biotech Plc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Trinity Biotech Plc's industry peers?
17 issuers in our coverage, TRIB included, share the SEC industry code In Vitro & In Vivo Diagnostic Substances. The largest are: Idexx Laboratories Inc /De (IDXX), Lantheus Holdings, Inc. (LNTH), Neogen Corp (NEOG), Celldex Therapeutics, Inc. (CLDX), Intellia Therapeutics, Inc. (NTLA), Quidelortho Corp (QDEL).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.